Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs ALLEGRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Seasonal allergic rhinitis,Chronic idiopathic urticaria
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
60 mg orally twice daily or 180 mg orally once daily.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is approximately 14.4 hours in healthy adults, allowing for twice-daily dosing. In patients with renal impairment, half-life may be prolonged (up to 59 hours in severe impairment).
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Minimally metabolized; undergoes hepatic metabolism via CYP3A4 to a lesser extent; mainly excreted unchanged in feces and urine.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Fexofenadine is primarily excreted unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for the majority of fecal elimination. Renal elimination is minimal due to extensive tubular reabsorption.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
60-70% bound, primarily to albumin and alpha-1-acid glycoprotein.
4-6 L/kg; large Vd indicates extensive tissue distribution
Vd is 5.4-6.7 L/kg, indicating extensive extravascular distribution. This large Vd reflects wide tissue penetration, though fexofenadine does not cross the blood-brain barrier significantly.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral bioavailability is approximately 33% (range 20-50%), with food reducing absorption by up to 20%. The absolute bioavailability is low due to first-pass metabolism and efflux transport (P-glycoprotein).
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
For GFR < 30 m L/min: 60 mg orally once daily.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
No adjustment required for hepatic impairment.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Children 6-11 years: 30 mg orally twice daily; Children ≥12 years: same as adult.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No specific adjustment; use with caution due to potential renal impairment.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Renal impairment: reduce dose in patients with Cr Cl < 80 m L/min; avoid use with known hypersensitivity; caution in patients with hepatic impairment.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypersensitivity to fexofenadine or any component of the formulation; severe renal impairment (Cr Cl < 30 m L/min) for the tablet formulation.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Fruit juices (apple, orange, grapefruit) reduce fexofenadine absorption by up to 36%, 36%, and 20% respectively; avoid concomitant intake within 4 hours; food does not significantly affect absorption, but administration with high-fat meal may slightly delay absorption; no specific food restrictions beyond fruit juice timing.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Fexofenadine (ALLEGRA) is classified as FDA Pregnancy Category C. Animal studies in rats and rabbits at doses up to 3 and 7 times the maximum recommended human dose (MRHD) respectively showed no evidence of teratogenicity. However, there are no adequate and well-controlled studies in pregnant women. First trimester: Limited human data; theoretical risk based on lack of data. Second and third trimesters: No known specific fetal risks; antihistamines in late pregnancy may cause uterine irritability and neonatal withdrawal symptoms (tremors, irritability) if used near term. Overall, risk is considered low but not zero.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Fexofenadine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 1.0. Based on a study, an exclusively breastfed infant would receive a dose of about 0.45% of the maternal weight-adjusted dose, which is considered negligible. No adverse effects have been reported in breastfed infants. The American Academy of Pediatrics considers fexofenadine compatible with breastfeeding. However, caution is advised for premature infants or those with renal impairment.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No specific dose adjustments are recommended during pregnancy due to minimal changes in pharmacokinetics. However, pregnancy can increase volume of distribution and renal blood flow, but studies show that fexofenadine exposure (AUC) is similar between pregnant and non-pregnant women. Dosing remains 60 mg twice daily or 180 mg once daily for seasonal allergies. For patients with renal impairment (creatinine clearance <80 m L/min), reduce starting dose to 60 mg once daily regardless of pregnancy status.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
ALLEGRA (fexofenadine) is a non-sedating antihistamine; avoid co-administration with fruit juices (apple, orange, grapefruit) as they reduce absorption; onset within 1 hour, duration 12-24 hours; dose adjustment needed in renal impairment (Cr Cl <80 m L/min): start 60 mg once daily; not significantly metabolized by CYP450, low drug interaction potential; acts as a P-glycoprotein substrate.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take on an empty stomach with water for best absorption.,Do not take with fruit juices (apple, orange, grapefruit) as they decrease effectiveness.,May cause drowsiness in rare cases; avoid driving if affected.,Use consistently for best symptom control; do not exceed recommended dose.,If you have kidney disease, consult your doctor before use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs ALLEGRA, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. ALLEGRA is a Antihistamine (Nonsedating) that works by Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and ALLEGRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of ALLEGRA is: 60 mg orally twice daily or 180 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and ALLEGRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. ALLEGRA is classified as Category C. Fexofenadine (ALLEGRA) is classified as FDA Pregnancy Category C. Animal studies in rats and rabbits at doses up to 3 and 7 times the maximum recommended human dose (MRHD) respecti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.